Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Karyopharm Therapeut (KPTI)

Karyopharm Therapeut (KPTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,069,942
  • Shares Outstanding, K 62,790
  • Annual Sales, $ 30,340 K
  • Annual Income, $ -178,410 K
  • 60-Month Beta 2.59
  • Price/Sales 45.32
  • Price/Cash Flow N/A
  • Price/Book 19.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.66
  • Number of Estimates 6
  • High Estimate -0.61
  • Low Estimate -0.74
  • Prior Year -0.96
  • Growth Rate Est. (year over year) +31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.98 +0.35%
on 01/17/20
20.09 -15.18%
on 01/09/20
-0.03 (-0.18%)
since 12/17/19
3-Month
10.53 +61.82%
on 10/18/19
20.09 -15.18%
on 01/09/20
+6.18 (+56.91%)
since 10/17/19
52-Week
3.92 +334.69%
on 03/01/19
20.09 -15.18%
on 01/09/20
+7.33 (+75.49%)
since 01/17/19

Most Recent Stories

More News
BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU

The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.

MRK : 90.97 (-0.23%)
RHHBY : 42.4200 (+1.60%)
KPTI : 17.04 (-9.51%)
BLRX : 2.48 (+0.40%)
Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I

Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.

AGN : 192.68 (-0.59%)
RIGL : 2.88 (-3.68%)
ACRS : 1.84 (-6.60%)
KPTI : 17.04 (-9.51%)
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO(R) (selinexor) and Provides Commercial Update

-- XPOVIO Unaudited Net Product Sales of between $17 and $18 Million for Fourth Quarter 2019 and between $30 and $31 Million for the Full Year 2019 --

KPTI : 17.04 (-9.51%)
Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics

Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics

TNK : 22.36 (+2.10%)
RUBI : 10.13 (-1.75%)
KPTI : 17.04 (-9.51%)
SAVA : 8.25 (-4.40%)
TALO : 28.67 (+0.21%)
5 Stocks With Recent Price Strength for Spectacular Returns

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

TNK : 22.36 (+2.10%)
RUBI : 10.13 (-1.75%)
KPTI : 17.04 (-9.51%)
SAVA : 8.25 (-4.40%)
TALO : 28.67 (+0.21%)
Karyopharm to Present at the 38th Annual J.P. Morgan Healthcare Conference

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 38th Annual J.P. Morgan...

JPM : 138.20 (+0.69%)
KPTI : 17.04 (-9.51%)
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase...

KPTI : 17.04 (-9.51%)
Karyopharm Submits New Drug Application to U.S. FDA for XPOVIO(R) (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking...

KPTI : 17.04 (-9.51%)
Karyopharm Presents XPOVIO(R) (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting

-- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis(R) and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with Heavily...

KPTI : 17.04 (-9.51%)
Karyopharm Reports New and Updated XPOVIO(R) (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting

-- All Oral Regimen of Once Weekly Selinexor in Combination with Daily Pomalyst and Low Dose Dexamethasone Demonstrates 56% Overall Response Rate in Pomalyst-Naive and Revlimid-Relapsed or -Refractory...

KPTI : 17.04 (-9.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade KPTI with:

Business Summary

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States.

See More

Key Turning Points

2nd Resistance Point 19.55
1st Resistance Point 18.29
Last Price 17.04
1st Support Level 16.38
2nd Support Level 15.73

See More

52-Week High 20.09
Last Price 17.04
Fibonacci 61.8% 13.91
Fibonacci 50% 12.01
Fibonacci 38.2% 10.10
52-Week Low 3.92

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar